Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
A Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-02-05
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 490
- Registration Number
- NCT04256421
- Locations
- 🇺🇸
Texas Oncology Cancer Center, Austin, Texas, United States
🇺🇸Virginia Cancer Specialists, Fairfax, Virginia, United States
🇺🇸Blue Ridge Cancer Care, Roanoke, Virginia, United States
RLY-1971 in Subjects With Advanced or Metastatic Solid Tumors
- First Posted Date
- 2020-02-05
- Last Posted Date
- 2023-01-31
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 56
- Registration Number
- NCT04252339
- Locations
- 🇺🇸
Florida Cancer Specialists - Sarasota, Sarasota, Florida, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokinetics of SC Versus IV Mosunetuzumab + Len in Participants With Follicular Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2020-01-29
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 237
- Registration Number
- NCT04246086
- Locations
- 🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸Swedish Medical Center; IDS Pharmacy, Seattle, Washington, United States
🇨🇳the First Hospital of Jilin University, Changchun, China
A Study to Evaluate the Efficacy and Safety of Polatuzumab Vedotin in Combination With Bendamustine and Rituximab Compared With Bendamustine and Rituximab Alone in Chinese Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL).
- Conditions
- Interventions
- First Posted Date
- 2020-01-22
- Last Posted Date
- 2023-03-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 42
- Registration Number
- NCT04236141
- Locations
- 🇨🇳
Jiangsu Province Hospital (the First Affiliated Hospital With Nanjing Medical University), Nanjing City, China
🇨🇳Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan City, China
🇨🇳West China Hospital, Sichuan University, Chengdu, China
A Trial To Evaluate The Efficacy And Safety Of Multiple Combination Therapies In Participants With Chronic Hepatitis B
- Conditions
- Interventions
- First Posted Date
- 2020-01-13
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 281
- Registration Number
- NCT04225715
- Locations
- 🇨🇳
Ruijin Hospital Shanghai Jiaotong University School of Medicine, Shanghai City, China
🇺🇸Inland Empire Liver Foundation, Rialto, California, United States
🇺🇸Quest Clinical Research, San Francisco, California, United States
A Study to Investigate the Effect of Impaired Hepatic Function on the Pharmacokinetics of Entrectinib in Volunteers With Different Levels of Hepatic Function
- First Posted Date
- 2020-01-13
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 38
- Registration Number
- NCT04226833
- Locations
- 🇨🇿
Pharmaceutical Research Associates CZ, s.r.o., Praha 7, Czechia
🇸🇰Summit Clinical Research s.r.o.; Oddelenie internej mediciny a klinickej farmakologie, Bratislava, Slovakia
🇭🇺CRU Hungary Kft, Miskolc, Hungary
A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
- Conditions
- Interventions
- First Posted Date
- 2020-01-10
- Last Posted Date
- 2024-10-07
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 223
- Registration Number
- NCT04222972
- Locations
- 🇺🇸
UC Irvine Medical Center, Orange, California, United States
🇺🇸Southern California Kaiser Permanente, San Diego, California, United States
🇦🇷Hospital Britanico; Oncologia, Buenos Aires, Argentina
A Study To Evaluate The Efficacy And Safety Of Obinutuzumab In Patients With ISN/RPS 2003 Class III Or IV Lupus Nephritis
- Conditions
- Interventions
- First Posted Date
- 2020-01-09
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 271
- Registration Number
- NCT04221477
- Locations
- 🇺🇸
North Shore University Hospital, Manhasset, New York, United States
🇺🇸University of Texas Southwestern, Dallas, Texas, United States
🇩🇪Universitaetsmedizin Johannes Gutenberg; Rheumatologie, Mainz, Germany
A Study of Bevacizumab, Carboplatin, and Paclitaxel or Pemetrexed With or Without Atezolizumab in Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (IMpower151)
- Conditions
- Interventions
- First Posted Date
- 2019-12-11
- Last Posted Date
- 2024-07-19
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 305
- Registration Number
- NCT04194203
- Locations
- 🇨🇳
Guangxi Cancer Hospital of Guangxi Medical University, Nanning City, China
🇨🇳First Affiliated Hospital of Medical College of Xi'an Jiaotong University, Xi'an, China
🇨🇳Nan Tong Tumor Hospital, Nantong City, China
A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Patients With PIK3CA-Mutant, Hormone Receptor-Positive, Her2-Negative, Locally Advanced or Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-12-09
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 325
- Registration Number
- NCT04191499
- Locations
- 🇪🇸
Clinica Universitaria de Navarra; Servicio de Oncologia, Pamplona, Navarra, Spain
🇪🇸Hospital Universitario de Canarias;servicio de Oncologia, La Laguna, Tenerife, Spain
🇪🇸Hospital del Mar; Servicio de Oncologia, Barcelona, Spain